Freenome had four patents in artificial intelligence during Q1 2024. Freenome Inc’s patent filed in Q1 2024 describes a method using methylation signals in cell-free DNA to train a machine learning model for detecting tumors or disease progression. This method involves extracting DNA, sequencing for methylation, detecting abnormal signals, and training the model to classify individuals into different groups such as healthy, cancer, or disease subtype/stage. It can be used for predicting, monitoring treatment response, tumor load, relapse, or cancer development. GlobalData’s report on Freenome gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Freenome Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Freenome grant share with artificial intelligence as a theme is 25% in Q1 2024. Grant share is based on the ratio of number of grants to total number of patents.

Recent Patents

Application: Methods and systems for detecting cancer via nucleic acid methylation analysis (Patent ID: US20240084397A1)

The patent filed by Freenome Inc. describes methods and systems for screening or detecting tumors and monitoring disease progression using cell-free nucleic acids, particularly cell-free DNA. The method involves detecting methylation signals in identified genomic regions to train a machine learning model that can classify populations of individuals into categories such as healthy, cancerous, or specific disease subtypes or stages. This approach can be used for predicting, prognosticating, and monitoring response to treatment, tumor load, relapse, or cancer development. The patent also includes a methylation signature panel comprising genomic regions associated with cell proliferative disorders, which can be used to distinguish between subjects with and without these disorders, including various types of cancer and different stages of cancer.

Furthermore, the patent outlines a method for training a machine learning classifier to differentiate between subjects with cell proliferative disorders and those without, using measured values from differentially-methylated genomic regions associated with these disorders. The classifier is trained to identify healthy subjects with cell proliferative disorders accurately. Additionally, the patent describes a method for determining the methylation profile of cell-free DNA samples from subjects by converting unmethylated cytosines to uracils, enriching for sequences corresponding to the methylation signature panel, determining nucleic acid sequences, and aligning them to a reference sequence. This process allows for the identification of methylation patterns associated with specific cell proliferative disorders, aiding in diagnosis and monitoring of disease progression.

To know more about GlobalData’s detailed insights on Freenome, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.